Login / Signup
Takashi Nakada
ORCID
Publication Activity (10 Years)
Years Active: 2024-2024
Publications (10 Years): 2
Top Topics
High Glucose
Dna Damage
Cell Cycle Arrest
Renal Cell Carcinoma
Top Venues
Molecular cancer therapeutics
</>
This page only lists publications with an associated author ORCID identifier.
Publications
</>
Hirokazu Suzuki
,
Shotaro Nagase
,
Chiemi Saito
,
Atsuko Takatsuka
,
Motoko Nagata
,
Kokichi Honda
,
Yuki Kaneda
,
Yumi Nishiya
,
Tomoyo Honda
,
Tomomichi Ishizaka
,
Kensuke Nakamura
,
Takashi Nakada
,
Yuki Abe
,
Toshinori Agatsuma
Raludotatug Deruxtecan, a CDH6-Targeting Antibody-Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, is Efficacious in Human Ovarian and Kidney Cancer Models.
Molecular cancer therapeutics
(2024)
Hirokazu Suzuki
,
Shotaro Nagase
,
Chiemi Saito
,
Atsuko Takatsuka
,
Motoko Nagata
,
Kokichi Honda
,
Yuki Kaneda
,
Yumi Nishiya
,
Tomoyo Honda
,
Tomomichi Ishizaka
,
Kensuke Nakamura
,
Takashi Nakada
,
Yuki Abe
,
Toshinori Agatsuma
Raludotatug Deruxtecan, a CDH6-Targeting Antibody-Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models.
Molecular cancer therapeutics
23 (3) (2024)